Buildit, et al: After reading the contract, it appears GNBT submits an invoice as expenses are incurred and up to a total of $1 million in expense, subject to some exceptions. The next steps are delivery of the vaccine, human trials, and efficacy studies before the license fee ($5 mil plus 20% per vaccine used) is executed. There are a number of exceptions and additions and several confidentiality provisions. So, I'm left with the following: "I don't know wtf is going on."!!
If I were Joe & co., I wouldn't release anything unless the Chinese OK'd it.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links